Form 4 for RMD ResMed|
Accepted 2023-11-15 00:00:00 ET · period of report 2023-11-13 · accession 0001127602-23-027463 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-11-15 | 2023-11-13 | RMD | Farrell Michael J. | CEO | F - Tax | $143.60 | -8,452 | 446.2K | -2% | -$1.21M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | ResMed Common Stock | 2023-11-13 | F | D | 2,181.29 | $143.60 | 440,986 | D | — | — | (F4) Includes 78.152 shares of ResMed stock purchased on October 31, 2023, through the ResMed Employee Stock Purchase Plan. |
| 2 | Common | ResMed Common Stock | 2023-11-13 | F | D | 3,037.91 | $143.60 | 443,167 | D | — | — | |
| 3 | Common | ResMed Common Stock | 2023-11-13 | F | D | 3,232.71 | $143.60 | 446,205 | D | — | — |